WallStSmart
KRYS

Krystal Biotech Inc

NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY

$259.95
-3.46% today

Updated 2026-04-29

Market cap
$7.65B
P/E ratio
38.06
P/S ratio
19.66x
EPS (TTM)
$6.83
Dividend yield
52W range
$123 – $298
Volume
0.3M

Krystal Biotech Inc (KRYS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+43.4%
Last 4 quarters
Revenue YoY growth
+17.5%
Most recent quarter
EPS YoY growth
+11.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-2.4%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-12.5%
2025-08-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-17$1.70+7.6%$276.45$283.29+2.5%
2025-11-03$2.66+144.0%$197.51$203.26+2.9%
2025-08-04$1.29+5.7%$156.98$137.35-12.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$1.58$1.70+7.6%$107.11M+17.5%
2025-09-30$1.09$2.66+144.0%$97.80M+16.6%
2025-06-30$1.22$1.29+5.7%$96.04M+36.6%
2025-03-31$1.03$1.20+16.1%$88.18M+94.9%
2024-12-31$1.85$1.53-17.4%$91.14M+116.3%
2024-09-30$0.90$0.91+1.1%$83.84M+879.9%
2024-06-30$0.58$0.53-8.6%$70.28M
2024-03-31$0.15$0.03-80.0%$45.25M
2023-12-31$-0.38$0.30+178.9%$42.14M
2023-09-30$-0.29$-0.69-137.9%$8.56M
2023-06-30$-0.74$-1.25-68.9%

Frequently asked questions

Has Krystal Biotech Inc beaten earnings estimates?
Krystal Biotech Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +43.4% over the last 4 quarters.
How does KRYS stock react to earnings?
KRYS stock has moved an average of -2.4% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Krystal Biotech Inc's revenue growth rate?
Krystal Biotech Inc reported year-over-year revenue growth of +17.5% in its most recent quarter, with EPS growing +11.1% year-over-year.